5-(2-fluorophenyl)-1H-pyrrole-3-carbonitrile NEW

‌Vonoprazan Fumarate Intermediate (CAS 1240948-77-9)‌
Google Keywords: Vonoprazan Fumarate Intermediate, CAS 1240948-77-9, PPI Drug Synthesis, Gastric Acid Inhibitor, GMP Pharmaceutical Intermediates

🌟 ‌Product Overview‌

‌Vonoprazan Fumarate Intermediate‌ (CAS 1240948-77-9) is a high-purity chemical intermediate critical for synthesizing ‌Vonoprazan Fumarate‌, a next-generation potassium-competitive acid blocker (P-CAB) used to treat gastroesophageal reflux disease (GERD) and gastric ulcers. This intermediate ensures efficient and scalable production of APIs with strict impurity control.

• ‌Primary Function‌: Enables precise synthesis of Vonoprazan Fumarate, optimizing yield and process stability.

• ‌Applications‌: Acid-related disorder therapies, generic drug development, and clinical trial material preparation.

✅ ‌Key Advantages‌

🔹 ‌Ultra-High Purity‌ | ≥99.5% (HPLC/GC verified) | Low residual solvent levels (<30 ppm).
🔹 ‌Process Efficiency‌ | Supports batch-to-batch consistency in large-scale API manufacturing.
🔹 ‌Regulatory Compliance‌ | Meets ICH Q11, USP/EP standards, and GMP guidelines.

🧪 ‌Applications‌

1. ‌GERD/Gastric Ulcer Treatments‌: Core component in Vonoprazan Fumarate API production.

2. ‌Clinical Formulation‌: Used in preclinical and phase I-III trial material preparation.

3. ‌Generic Drug Synthesis‌: Key intermediate for post-patent API commercialization.

📜 ‌Quality Assurance‌

• ‌Testing Methods‌: HPLC, GC, NMR, and LC-MS for identity, purity, and impurity profiling.

• ‌Standards‌: Complies with USP <1086>, EP 10.0, and ISO 9001:2015 quality systems.

📈 ‌Market Trends‌

The global ‌GERD treatment market‌ is projected to reach ‌$6.8 billion by 2028‌ (CAGR 4.7%), driven by rising demand for potent acid inhibitors like Vonoprazan. As P-CAB drugs gain traction over traditional PPIs, this intermediate is pivotal in meeting pharmaceutical innovation needs.

Accelerate your API production with Vonoprazan Fumarate Intermediate – purity, scalability, and compliance for cutting-edge gastrointestinal therapies.